InvestmentJun 25, 2026, 09:29 AM
Helus Pharma Closes $50M Underwritten Offering
AI Summary
Helus Pharma announced the closing of its previously announced underwritten offering, generating aggregate gross proceeds of US$50 million. The company offered 10,309,280 common shares at US$4.85 per share. The net proceeds are intended to advance the company's HLP003, HLP004, and HLP005 programs, as well as for working capital and general corporate purposes.
Key Highlights
- Closed underwritten offering of 10,309,280 common shares.
- Generated aggregate gross proceeds of US$50 million.
- Offering price was US$4.85 per common share.
- Net proceeds to fund HLP003 (Phase 3), HLP004, and HLP005 programs.
- Also for working capital and general corporate purposes.
- Paid US$3 million cash commission to underwriters.
Price Impact
More from HELP